The apicoplast is an essential plastid organelle found in Plasmodium spp parasites, which 20 contains several clinically validated anti-malarial drug targets. A chemical rescue screen 21 identified MMV-08138 from the "Malaria Box" library of growth-inhibitory anti-malarial 22 compounds as having specific activity against the apicoplast. MMV-08138 inhibition of blood-23 stage P. falciparum growth is stereospecific and potent, with the most active diastereomer 24 demonstrating an EC 50 =110 nM. Whole-genome sequencing of 3 drug-resistant parasite 25 populations from two independent selections revealed E688Q and L244I mutations in P. 26 falciparum IspD, an enzyme in the MEP isoprenoid precursor biosynthesis pathway in the 27
Introduction 34
Despite encouraging progress over the past decade, malaria caused by Plasmodium spp 35 parasites continues to pose an enormous disease burden (1) . New anti-malarials with novel 36 mechanisms of action are needed to circumvent existing or emerging drug resistance (2). The 37 apicoplast is a plastid organelle unique to Plasmodium spp (and other pathogenic Apicomplexa 38 parasites) and a key target for development of new anti-malarials. Due to its prokaryotic origin 39 and evolution as a secondary plastid, it contains pathways that have no counterpart in the human 40 host (3, 4). In Plasmodium, the apicoplast is essential for both intraerythrocytic and intrahepatic 41 development in the human host (5, 6). 42
Despite efforts to develop inhibitors of apicoplast function, to date, there are no primary 43 agents for treatment of acute malaria whose mechanism of action targets this unusual plastid 44 organelle. Antibiotics that inhibit prokaryotic transcription and translation, such as doxycycline 45 and clindamycin, block expression of the apicoplast genome and are active against Plasmodium 46 parasites (5). Unfortunately, these drugs show a "delayed death" phenotype, in which growth 47 inhibition occurs only after 2 replication cycles (96 hours). The slow kinetics limit the use of 48 doxycycline and clindamycin to chemoprophylaxis or as a partner drug in combination therapies 49 with faster-acting compounds. Fosmidomycin, which inhibits the enzyme DoxR/IspC for MEP 50 isoprenoid precursor biosynthesis in the apicoplast, has immediate onset but shows high 51 recrudescence rates clinically when used as monotherapy (7, 8) . The efficacy of fosmidomycin-52 based combination therapy is currently being evaluated with mixed results (9-12). Development 53 of new apicoplast inhibitors as anti-malarials has been challenging due to gaps in our knowledge 54 of apicoplast biology and specific pathways and proteins to target. 55
4
As an alternative to target-specific approaches, several large-scale "chemical genetics" 56 screens have been carried out to identify compounds with anti-malarial activity, defined by 57 growth inhibition of P. falciparum blood cultures (13-15). This approach 1) directly measures a 58 disease-relevant phenotype while 2) interrogating all cellular pathways in 3) an unbiased manner 59 to identify the most drug-sensitive nodes, even if the target proteins were not previously obvious 60 or even characterized (16). Forward chemical genetics is particularly useful in Plasmodium, 61
where the lack of practical methods for large-scale mutant analysis to deconvolute new pathways 62 or conditional knockouts to investigate essential functions prohibits genetic approaches that have 63 been so powerful in the past in other model systems (17) . However, major drawbacks to this 64 approach are that, once a compound is identified as growth inhibitory, its target protein or 65 pathway may be difficult to decipher and may be one of multiple targets if the compound is non-66
specific (16). 67
Our previous work demonstrated that the essential function of the apicoplast in P. 68 falciparum blood-stage parasites is the production of isoprenoid precursors, isopentenyl 69 pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMAPP), by the prokaryotic 70 MEP pathway (18). The remaining plastid pathways are required to house this critical 71 biosynthetic activity and to supply it with cofactors and substrates. We demonstrated this by 72 generating P. falciparum parasites that lacked apicoplasts but could be chemically rescued by 73 addition of IPP to the growth media. The IPP chemical rescue presents an exciting opportunity to 74 carry out a simple pathway-specific screen to identify small molecules that target the apicoplast. 75
Compounds whose anti-malarial growth inhibition is eliminated by the addition of IPP would be 76 revealed to target essential pathways for apicoplast function. IPP has already been shown to 77 rescue growth inhibition by fosmidomycin and antibiotics (18). This chemical rescue screen 78 9 (derisilab.ucsf.edu/software/PRICE/) (21). Reads with an average per base quality score of <1% 171 probability of an incorrect base were retained and then mapped to the 3D7 reference genome 172 (PlasmoDB release 9.3) using the short read alignment software bowtie, keeping reads that were 173 uniquely mapping with no more than a single mismatch, excluding five nucleotides trimmed 174 from both ends of each read. Following mapping, alignments were evaluated for the presence of 175 copy number variants (CNVs) and mutations. For CNVs and coverage calculations, the R-176 package "CNV-Seq" was used in conjunction with samtools to detect amplifications or deletions 177 with a p-value of <0.001, using a 3 kb sliding window relative to the parental strain used to 178 initiate each drug selection (22, 23). For mutation detection, a custom written python package 179 (available upon request) was used to compare each bowtie alignment in the drug selected strain 180 relative to the parental strain and the 3D7 reference genome. For each detected variant, the 181 number of reads featuring that variant is reported, as well as the percentage of the total reads for 182 that nucleotide position and variant. Only variants covered by a depth of 30 or more reads were 183 considered reliable. 184
185

Sanger sequencing 186
The plasmodium IspD gene was PCR amplified from genomic DNA using the primer 187 pair, 0.5F and 8R. PCRs contained 0.5 µM primers, 0.2 mM dNTPs (80% AT), 0.04 U/µL 188 (IPTG) at an OD 600 of 0.5 and protein expression allowed to proceed for 3.5 h. 231
Bacterial cells were harvested by centrifugation at 7000 g, and the cell pellet was suspended in 232 50 mM phosphate buffer, 300 mM NaCl, 20 mM imidazole, pH 8.0 containing lysozyme (1 233 mg/ml), and Complete EDTA-free protease inhibitor tablet (Roche) (one tablet per 25 mL 234 buffer). Cells were incubated for 30 min at rt and then disrupted by sonication (20% amplitude, 6 235 bursts of 10 s with cooling in an ice bath for 10 s between each burst). After centrifugation at 236 20,000 g for 30 min at 4 °C, the supernatant was recovered and loaded onto a HisTrap HP 1 mL 237 column (GE Healthcare Life Sciences) equilibrated in 50 mM phosphate buffer, 300 mM NaCl, 238 and 20 mM imidazole using an AKTApure chromatography system. The column was washed 239 with the same buffer and eluted using an imidazole gradient (20-500 mM). 
MMV-08138 inhibition is stereospecific 291
A set of 29 compounds, which were structurally related to MMV-08138 but with 292
unknown stereochemistry, was also tested for antimalarial growth inhibition and IPP rescue 293 ( Figure S3 ; Table S1 ). These compounds were all less active than MMV-08138, either due to 294 alterations in important functional groups or improper stereochemistry. Notably, MMV-08138 295 contains 2 stereocenters resulting in 4 possible diastereomers of this compound. Evaluation of 296 its activity had thus far been carried out with an unspecified racemic mixture that could contain 297 both active and inactive diastereomers (Figure 1) . However, knowledge of the stereospecificity 298 of the inhibitor will be important for further structure-activity optimization and in vivo studies. 299
Therefore, we obtained all 4 chirally-pure diastereomers and evaluated each for its IPP-rescued 300 growth inhibitory activity (Table 1; Figure S4 ). The most active compound was the 1R,3S 301 conformer with an EC 50 of 110 nM which showed IPP rescue up to 25 µM. The 1R,3R 302 conformer was at least 30-fold less active but still showed IPP rescuable activity up to 25 µM. 303
The 1S,3R conformer inhibited growth at EC 50 18.6 µM which was minimally rescued with IPP. 304
Finally, the 1S,3S conformer was completely inactive. The stereospecificity of the growth 305 inhibition indicated drug binding to a specific cellular target. 306 307
MMV-08138-resistant populations can be selected under drug pressure 308
In order to clarify the mechanism of action of MMV-08138, parasites resistant to MMV-309 08138 were generated in 2 independent selections (Figure 2A ). In the first selection, susceptible 310 blood-stage P. falciparum parasites were directly exposed to a lethal dose of a racemic mixture 311 of MMV-08138. Resistant parasites emerged after 20 days of continuous drug exposure. The 312 resistant population from this selection, designated 08138R1, was determined to have an EC 50 313 that was 12.7-fold greater than the EC 50 of the initial susceptible population against the 1R,3S 314 diastereomer of MMV-08138 ( Figure 2B ). In the second selection, susceptible parasites were 315 exposed to the 1R,3S diastereomer of MMV-08138 at a dose equal to IC 75 . Resistant parasites, 316 designated 08138R2, emerged after 43 days of continuous drug exposure and were found to have 317 EC 50 that was 3.5-fold greater than that of the initial susceptible population ( Figure 2B ). These 318 08138R2 parasites were then exposed to a lethal dose of MMV-08138 to generate a population, 319 08138R3, with EC 50 =19.2-fold greater than that of the initial population after a total of 75 days 320 of continuous drug exposure ( Figure 2B) . 321 322
Whole-genome sequencing of drug-resistant populations identifies mutations in IspD 323
Each of these 3 drug resistant populations, 08138R1, 08138R2, and 08138R3, and parent 324 W2 strains used to begin each selection were subjected to whole genome sequencing. After 325 quality filtering and alignment to the reference sequence, the average coverage ranged from 136-326 fold to 366-fold for the 14 chromosomes, >1000-fold for the mitochondria, and >300-fold for 327 the plastid. Each dataset was evaluated for the presence of copy number variants (CNVs), such 328 as amplified regions. Other than the variable sequences proximal to the telomeres, no CNVs of 329 significance (p<0.001) were detected relative to the drug sensitive parental strain (Table S2) . 330
Unlike other examples of drug resistance in P. falciparum (27), this result suggests that a simple 331 16 amplification of a drug target or resistance determinant was not responsible for the observed 332 resistance in these three selections. 333
Using the mapped reads for each resistant population, genomic mutations were detected 334 by comparison to the reference sequence and the parental strain. Our criteria for mutations 335 relevant to the selection consisted of non-synonymous mutations in which >90% of the reads at 336 that position were "mutant" with respect to the parent and reference. Mutations relative to the 337 reference strain, but which were identical in both the parental strain and the selected populations, 338
were not considered relevant. Using these criteria, we detected 3 non-synonymous mutations in 339 08138R1, 3 in 08138R2, and 2 in 08138R3 (Table 2 ). In all three resistant populations, the only 340 mutated gene shared in common was PF3D7_0106900, which is the putative 2-C methyl-D-341 erythritol 4-phosphate cytidylyltransferase (IspD) enzyme of the MEP isoprenoid precursor 342 pathway (Figure 3) . One mutation found in 08138R2 was a change from glutamate to glutamine 343 at position 688 in IspD. Another mutation was found in both 08138R1 and 08138R3, a change 344 from leucine to isoleucine at position 244 of IspD. 345
To confirm the presence of the identified mutations in IspD, the gene was PCR amplified 346 from genomic DNA of the parent and resistant populations and the entire gene sequenced using 347 the Sanger method ( Figure S5 ). All the IspD mutations observed in the whole genome 348 sequencing data were validated by Sanger sequencing ( Figure 3A ). In the case of population 349 08138R2, which was only selected to 91% mutant call purity, the PCR amplification product of 350
IspD was cloned into a vector, transformed into E. coli, and 11 colonies selected for sequencing. 351
Ten colonies showed the E688Q mutation while one colony did not show the mutation, in 352 agreement with the whole genome sequencing data. Several mutations relative to the reference 353 strand were also shared by both the parental and selected populations ( Figure S6 ). This data 354 supports the notion that the anti-apicoplast action of MMV8138 is due to inhibition of this 355 critical isoprenoid precursor biosynthesis enzyme, given that mutations in this gene suppress its 356 activity. A block level amino acid alignment of P. falciparum IspD with those from E. coli and 357
A. thaliana shows that PfIspD contains significant additional domains of unknown utility (Figure  358 3B). However, both of the reported mutations do occur proximal to conserved regions among 359 the homologs of IspD. 360 361
MMV-08138 inhibits P. falciparum IspD activity in vitro 362
To determine if MMV-08138 directly inhibits PfIspD, we heterologously expressed and 363 purified His and MBP-tagged PfIspD and measured its enzymatic activity using a pyrophosphate 364 release assay. The purified enzyme was active with a K m of 60.6 µM for MEP and a k cat of 0.16 365 s -1 ( Figure S7 ). In the presence of varying amounts of the 1R,3S-diastereomer of MMV-08138, 366 enzyme activity measured at saturating substrate concentrations was inhibited with an IC 50 of 7.0 367 nM (Figure 4 ; Table 1 ). Inhibition by MMV-08138 of PfIspD activity was stereospecific as the 368 other diastereomers of MMV-08138 were all less potent (Figure 4 ; Table 1 ). The IC 50 was 369 similar when PfIspD activity was measured at substrate concentrations equal to K m , when the 370 enzyme is not saturated ( Figure S7) . 371
Interestingly, MMV-08138 inhibits PfIspD activity but did not inhibit E. coli, A. thaliana, 372
or P. vivax IspD activity in vitro. We tested MMV-08138 in in vitro activity assays against MEP 373 pathway enzyme homologs from various organisms. MMV-08138 showed no enzyme inhibition 374 against E. coli DXS at up to 100 μM inhibitor, DXR/IspC at up 50 μM, or IspD, IspE, and IspF 375 at 10 μM ( Figure S8; (28-31) ). MMV-08138 also did not affect the enzyme activity of purified 376
A. thaliana or P. vivax IspD at up to 1 mM inhibitor ( Figure S9; (32, 33) . 377
Discussion 379
Both the genetic and biochemical evidence identify PfIspD, an enzyme in the key MEP 380 isoprenoid precursor biosynthesis pathway in the apicoplast, as the molecular target of MMV-381 08138. The determinants of resistance against MMV-08138 were two mutations in IspD. The 382 E688Q mutation was identified in 3.5-fold "low" resistant strain. Meanwhile, two independent 383 selections carried out with different protocols converged on the same L244I mutation, which was 384 identified in both higher (13-19 fold) resistant strains. In all three resistant populations, the only 385 mutated gene shared in common was IspD. Interestingly, the L244I yielded the higher resistance 386
phenotype, yet is a more subtle amino acid change compared to E688Q. Small amino acid 387 changes can result in pronounced resistance phenotypes, as an isoleucine-to-leucine mutation in 388 acetyl-CoA carboxylases has previously been demonstrated to confer herbicide resistance in 389 plants (34, 35) . 390
Based on the genetic results, further biochemical characterization demonstrated that 391 MMV-08138 acts by directly binding and inhibiting IspD enzymatic activity. Consistent with 392 this mechanism, the IC 50 of the inhibitor against purified PfIspD was comparable to the EC 50 393 against blood-stage P. falciparum parasites. The stereospecificity of the enzyme inhibition also 394 paralleled that of cell growth inhibition. Surprisingly, MMV-08138 did not inhibit the enzyme 395 activity of purified E. coli, A. thaliana, or P. vivax IspD (28, 32) . This may be due to structural 396 differences in IspD homologs in these species, as even the P. vivax and P. falciparum IspD share 397 only 31% identity. Further studies using the same detection assay and kinetic conditions to 398 compare IspD homologs will be required to confirm the selectivity of MMV-08138 for IspD 399 homologs from different species. 400
Further kinetic and structural characterization will be required to identify the mechanism 401 
